Definition and pathophysiology
Left ventricular (LV) thrombus is an intracavitary clot attached to the LV endocardium, typically overlying an akinetic or dyskinetic myocardial segment after myocardial infarction (MI). It is particularly associated with extensive anterior or transmural infarction, apical dysfunction, LV aneurysm formation, and reduced LV systolic function.
The principal mechanisms are the combination of an abnormal thrombogenic endocardial surface and blood stasis. During the acute infarction phase, endocardial inflammation and impaired regional contraction create conditions that favour thrombus formation. Extensive transmural septal infarction may also permit mural thrombi to develop over infarcted myocardium in either ventricle.
With contemporary imaging, LV thrombus has been reported in as many as 15% of patients after ST-segment elevation myocardial infarction (STEMI), with rates approaching 25% after anterior MI. Thrombi may form early, within 48–72 hours of infarction. Early thrombus formation is associated with poor short-term prognosis, although early mortality is usually related to the extent of myocardial injury and its complications—shock, reinfarction, myocardial rupture, and ventricular tachyarrhythmia—rather than embolization itself.
A thrombus may be:
Mural: flattened, fixed, and closely adherent to the endocardial surface.
Protruding or mobile: extending into the ventricular cavity, sometimes with independently mobile components.
Although a mural thrombus is attached to infarcted myocardium, superficial components may detach and embolize systemically. Observational data indicate approximately a fourfold greater risk of embolic events in patients with LV thrombus than in matched patients without thrombus.
Factors associated with embolization
Echocardiographic features suggesting increased embolic potential include:
Greater thrombus mobility.
Protrusion into the LV cavity.
Visualization on multiple imaging planes.
Location adjacent to hyperkinetic myocardium.
Large thrombus burden.
Cardiac magnetic resonance (CMR) can further characterize thrombus morphology and may assist in embolic-risk assessment.
Clinical presentation and symptoms
LV thrombus may be clinically silent and discovered during post-infarction imaging. When embolization occurs, presentation depends on the vascular territory involved and may include systemic arterial embolic manifestations. The source material does not provide a detailed catalogue of specific embolic syndromes.
Clinical suspicion should be heightened after:
Anterior STEMI.
A large or transmural infarction.
Persistent apical akinesis or dyskinesis.
LV aneurysm formation.
LVEF below 40%.
Ongoing or newly recognized LV systolic dysfunction.
A patient may also present because of complications of the underlying infarction or LV remodeling, including heart failure, ventricular arrhythmias, or recurrent ischemic symptoms. These manifestations do not by themselves establish the presence of thrombus.
Evaluation and physical examination
The physical examination is directed primarily toward the consequences of the infarction and LV dysfunction rather than toward thrombus itself. The thrombus is often asymptomatic and cannot be diagnosed reliably by examination alone.
Assessment should include evaluation for:
Hemodynamic instability or cardiogenic shock.
Clinical heart failure.
Recurrent ischemia or reinfarction.
Ventricular tachyarrhythmia.
Features suggesting systemic embolization.
In patients with recurrent chest pain and hemodynamic compromise after MI, mechanical complications should be considered. Transthoracic echocardiography (TTE) can help assess for these complications, although coronary angiography may be required when acute native-vessel or stent thrombosis must be excluded.
Diagnostics
Echocardiography
TTE is the principal initial imaging method for detecting LV thrombus and assessing the substrate on which it develops. The thrombus generally appears as a discrete, homogeneously echogenic, deformable mass abutting the endocardial border of an akinetic or dyskinetic segment.
The examination should evaluate:
LV regional wall motion.
Apical visualization.
LV systolic function.
Thrombus size, shape, mobility, and protrusion.
Presence of an LV aneurysm.
Associated mitral regurgitation and other post-infarction complications.
Echocardiography is less sensitive than CMR, particularly for small or mural thrombi. Its accuracy depends on pretest probability, image quality, and thrombus morphology. Mural thrombi are more difficult to identify than protruding or mobile thrombi.
Ultrasound-enhancing agents
Intravenous ultrasound-enhancing agents can substantially improve thrombus detection. Their use may approximately double the detection rate, with reported sensitivity up to 60% and positive predictive value of 93% in the cited material.
After acute anterior MI, contrast echocardiography may be considered when the apex is inadequately visualized on standard echocardiography.
Cardiac magnetic resonance
CMR should be considered when echocardiographic findings are equivocal or when clinical suspicion remains high despite a nondiagnostic echocardiogram. It provides improved characterization of LV thrombus and can detect thrombi that are missed by echocardiography.
CMR is also useful in the assessment of associated infarct characteristics, ventricular remodeling, aneurysm formation, and the structural substrate contributing to embolic risk.
Other imaging modalities
LV aneurysm can be diagnosed by:
Echocardiography.
CMR.
Computed tomography.
Left ventriculography.
The source material does not establish a preferred role for CT or ventriculography specifically in routine LV thrombus detection.
Electrocardiography
Persistent ST-segment elevation after MI may indicate a large infarct with regional wall-motion abnormality and poor microvascular reperfusion. It does not, however, prove the presence of an LV aneurysm or thrombus. Aneurysm diagnosis requires imaging.
New or dynamic recurrence of ST-segment elevation after the index infarction should raise concern for reinfarction. Interpretation may be difficult because normal ECG evolution after the initial MI can overlap with changes caused by recurrent infarction.
Biomarkers and laboratory findings
The source material does not describe specific laboratory markers for diagnosing LV thrombus. Cardiac biomarkers may remain elevated after the initial infarction, making it difficult to use them alone to distinguish recurrent infarction from the original event, particularly during the first 24 hours.
Diagnosis of LV thrombus is therefore imaging-based rather than biomarker-based.
Treatment and management
Anticoagulation for confirmed LV thrombus
For patients with confirmed LV thrombus, oral anticoagulant therapy with either a vitamin K antagonist (VKA) or a non-vitamin K oral anticoagulant (NOAC) should be considered for 3–6 months.
The choice of agent must be integrated with:
The need for concomitant antiplatelet therapy after MI or percutaneous coronary intervention.
Bleeding risk.
Clinical and imaging characteristics of the thrombus.
The extent of LV dysfunction and infarction.
Evidence of persistent thrombus or LV aneurysm.
The source material does not provide specific drug names, dosing regimens, target anticoagulation values, or protocols for combining anticoagulant and antiplatelet treatment.
Imaging-guided reassessment
Follow-up imaging is required to determine whether thrombus has resolved and whether the underlying substrate persists. In patients treated with anticoagulation, thrombus resolution has been observed in approximately 50% by one year and 75% by two years.
The duration of anticoagulation beyond the initial 3–6 months is not specified as a universal requirement. Continued treatment may be relevant when thrombus persists or when a residual LV aneurysm creates ongoing stasis and thrombotic risk.
LV aneurysm and thrombus
LV aneurysms are discrete dyskinetic outpouchings that preserve the integrity of the endocardium, myocardium, and epicardium. Common sites include the apex and basal inferior wall. Spontaneous echocardiographic contrast within an aneurysm indicates local blood stasis.
In the absence of anticoagulation, stagnant flow within an LV aneurysm may promote thrombus formation. Patients with large aneurysms, anterior MI, or LVEF below 40% are particularly susceptible.
Residual LV aneurysm after STEMI may justify long-term oral anticoagulation because of the risks of mural thrombosis and systemic embolization.
Management of associated LV remodeling
After MI, the LV may continue to enlarge and develop hypokinesis in noninfarcted regions, a process termed LV remodeling. Remodeling includes increased LV volume and changes toward a more globular ventricular geometry. This process may perpetuate regional stasis and promote thrombus formation.
Management therefore includes assessment and treatment of the associated ventricular dysfunction and post-infarction complications. The source material does not provide a complete pharmacological regimen for post-MI LV remodeling or heart failure.
Surgical and transcatheter treatment of aneurysm
Surgical aneurysmectomy is most likely to succeed when contractile function in the nonaneurysmal LV is relatively preserved. Surgical ventricular reconstruction performed with coronary artery bypass grafting reduces LV volume in patients with LVEF ≤35% but does not improve symptoms, exercise tolerance, or death or cardiac hospitalization outcomes in the cited evidence.
Guidelines nevertheless suggest that surgical ventricular remodeling performed during bypass surgery may be useful in selected patients with:
Intractable heart failure.
Large thrombus.
Persistent arrhythmias arising from an aneurysmal scar.
Transcatheter aneurysm exclusion remains investigational; technical implantation has generally been feasible, but outcome data are limited.
Drugs and practical considerations
Oral anticoagulants
Guideline-supported options for confirmed LV thrombus are:
| Drug category | Indication | Suggested duration in the source material | Practical considerations |
|---|---|---|---|
| Vitamin K antagonist | Confirmed LV thrombus | 3–6 months | Must be considered alongside concomitant antiplatelet therapy and bleeding risk |
| NOAC | Confirmed LV thrombus | 3–6 months | Preferred over VKA for de novo atrial fibrillation during ACS, but the source does not state that preference for LV thrombus specifically |
No doses or monitoring targets are provided in the source material.
Antiplatelet therapy
The source material emphasizes that anticoagulation decisions must account for the need for concomitant antiplatelet therapy after acute coronary syndrome or coronary intervention. It does not specify antiplatelet agents, doses, or combination strategies.
Guideline recommendations
The principal recommendations concerning LV thrombus after MI are:
| Recommendation | Class | Level |
|---|---|---|
| Consider CMR when echocardiographic images are equivocal or clinical suspicion of LV thrombus remains high | IIa | C |
| Consider oral anticoagulation with a VKA or NOAC for 3–6 months in confirmed LV thrombus | IIa | C |
| After acute anterior MI, consider contrast echocardiography when the apex is not adequately visualized | IIb | C |
These recommendations emphasize a stepwise approach: improve echocardiographic visualization when necessary, use CMR when uncertainty persists, and anticoagulate confirmed thrombus for a defined period with reassessment.
Prognosis and follow-up
Prognosis
The presence of LV thrombus is associated with a substantially higher risk of systemic embolism. However, early post-infarction mortality in patients with thrombus forming within 48–72 hours is more often attributable to the severity of the infarction and its complications than to embolization.
Overall prognosis is influenced by:
Resting LV systolic function.
The amount of residual potentially ischemic myocardium.
Susceptibility to serious ventricular arrhythmias.
Infarct size and location.
Persistence of LV aneurysm or thrombus.
The extent of LV remodeling.
LV aneurysm itself is associated with higher mortality, even after accounting for comparable LVEF. Sudden death is frequent in this setting, presumably in part because of the increased incidence of ventricular tachyarrhythmias. Loss of contractile function in the aneurysmal region can reduce stroke volume or increase LV end-diastolic volume, wall stress, and myocardial oxygen demand, potentially leading to heart failure.
Follow-up imaging
Follow-up should document:
Thrombus resolution or persistence.
Changes in LV size and systolic function.
Evolution of regional wall motion abnormalities.
Development or progression of LV aneurysm.
Ongoing spontaneous echocardiographic contrast or other evidence of stasis.
Embolic or bleeding complications of treatment.
Echocardiography is generally suitable for serial assessment, while CMR should be used when echocardiographic findings remain uncertain or when detailed characterization is clinically important.
Arrhythmic surveillance
Patients with extensive infarction, LV aneurysm, or marked LV dysfunction may also be at risk of serious ventricular arrhythmias. At hospital discharge, risk assessment incorporates LV function, residual ischemic myocardium, and markers of electrical instability, including ventricular ectopic activity, reduced heart-rate variability or baroreflex sensitivity, and abnormal signal-averaged ECG findings.
The source material does not define a specific follow-up schedule for LV thrombus itself. Follow-up timing should therefore be individualized according to thrombus characteristics, anticoagulation strategy, LV function, aneurysm status, and the occurrence of embolic or arrhythmic complications.
